-- Votes cast exclusively through the independent proxy in line with 
      COVID-19 Ordinance 3 of the Swiss government to combat the pandemic 
 
   -- Increase in the dividend from CHF 2.20 to CHF 2.30 per share 
 
   -- Lukas Braunschweiler, Heinrich Fischer, Oliver Fetzer, Karen Huebscher, 
      Christa Kreuzburg and Daniel R. Marshak re-elected as members of the 
      Board of Directors 
 
   -- Lukas Braunschweiler confirmed by shareholders as Chairman of the Board 
 
   -- Christa Kreuzburg, Oliver Fetzer and Daniel R. Marshak confirmed as 
      members of the Compensation Committee 
 
   -- All proposals relating to compensation approved 
 
   Männedorf, Switzerland, April 13, 2021 -- The Annual General 
Meeting of the Tecan Group (SIX Swiss Exchange: TECN) endorsed all 
motions proposed by the Board of Directors on April 13, 2021. The Annual 
General Meeting was held at the headquarters of the company, without 
personal attendance by shareholders. Voting rights could only be 
exercised through the independent proxy in line with the Federal Act on 
the Statutory Principles for Federal Council Ordinances on Combating the 
COVID-19 Epidemic and/or with the COVID-19 Ordinance 3 of the Swiss 
government to combat the pandemic. Tecan informed of the procedure on 
March 23, 2021. 
 
   Shareholders approved the Annual Report, the financial statements and 
the consolidated financial statements, and granted discharge to the 
Board of Directors and the Management Board. They agreed to an increase 
in the dividend from CHF 2.20 to CHF 2.30 per registered share. Half of 
the dividend, i.e., CHF 1.15, will be paid out from the available 
capital contribution reserve and is therefore not subject to withholding 
tax. The payout will take place on April 19, 2021. 
 
   All current members of the Tecan Board of Directors were confirmed by 
the shareholders for a term of one year: Heinrich Fischer, Dr. Oliver 
Fetzer, Dr. Karen Huebscher, Dr. Christa Kreuzburg, Dr. Daniel R. 
Marshak and Dr. Lukas Braunschweiler. Lars Holmqvist, a member of the 
Board of Directors since 2015, did not stand for re-election. Lukas 
Braunschweiler, Chairman of the Board of Directors, warmly thanked the 
departing member on behalf of the Board for his service over many years 
and the valuable contribution he had made to the development of the 
company with his proven industry expertise. 
 
   Until the Annual General Meeting in 2022, the Board of Directors will 
consist of six members. 
 
   Lukas Braunschweiler was re-elected as Chairman of the Board of 
Directors. The shareholders also confirmed Christa Kreuzburg, Oliver 
Fetzer and Daniel R. Marshak as members of the Compensation Committee. 
 
   Other proposals also approved 
 
   The shareholders voted on the conditions governing the compensation of 
the Board of Directors and Management Board for the following fiscal 
year, according to the Ordinance Against Excessive Compensation in 
Listed Stock Companies of the Swiss government (OaEC). They made a 
binding decision to endorse the proposed maximum total amount of 
compensation for fiscal year 2022 and also, for the Board of Directors, 
for the period until the 2022 Annual General Meeting. The 2020 
Compensation Report, which was submitted for an advisory vote, was also 
accepted by shareholders. 
 
   Ernst & Young AG, Zurich, was reappointed as the statutory auditors for 
fiscal year 2021. 
 
   Shareholders approved the motion proposed by the Board of Directors to 
appoint Proxy Voting Services GmbH, Zurich, as the independent proxy for 
the period up to the close of the Tecan Group 36(th) Annual General 
Meeting in 2022. 
 
   Key upcoming date 
 
   Tecan will publish the 2021 Interim Report on August 18, 2021. 
 
   About Tecan 
 
   Tecan (www.tecan.com) is a leading global provider of laboratory 
instruments and solutions in biopharmaceuticals, forensics and clinical 
diagnostics. The company specializes in the development, production and 
distribution of automation solutions for laboratories in the life 
sciences sector. Its clients include pharmaceutical and biotechnology 
companies, university research departments, forensic and diagnostic 
laboratories. As an original equipment manufacturer (OEM), Tecan is also 
a leader in developing and manufacturing OEM instruments and components 
that are then distributed by partner companies. Founded in Switzerland 
in 1980, the company has manufacturing, research and development sites 
in both Europe and North America and maintains a sales and service 
network in 52 countries. In 2020, Tecan generated sales of CHF 731 
million (USD 778 million; EUR 683 million). Registered shares of Tecan 
Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191). 
 
   For further information: 
 
   Tecan Group 
 
   Martin Braendle 
 
   Senior Vice President, Corporate Communications & IR 
 
   Tel. +41 (0) 44 922 84 30 
 
   Fax +41 (0) 44 922 88 89 
 
   https://www.globenewswire.com/Tracker?data=BgZrhzEwLDOE_kLldSm6Z0SPeE-K1odn8GPbU5JKFguNFykqVKMdRTjjxuK_fkNPO7UBYtIHZnhW0zSHek6Libod8Ay0vkBCejBeurJNIPM= 
investor@tecan.com 
 
   www.tecan.com 
 
   Attachment 
 
 
   -- Press Release 
      https://ml-eu.globenewswire.com/Resource/Download/bddda550-41e0-47d8-8598-c3fb65128ec7

(END) Dow Jones Newswires

April 13, 2021 11:45 ET (15:45 GMT)